 Gilead and Galapagos have released 52-week clinical trial data showing the durability of filgotinib in rheumatoid arthritis patients. The update comes as the partners close in on a FDA approval that will position them to compete with rival JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer. 